Deck Bio develops multi-target T cell engager immunotherapies for solid tumors.
Deck Bio has raised $3.1M in total funding. The most recent round was Seed. The last funding was announced in April 2026.
Deck Bio's investors include Mission BioCapital, BrightEdge - American Cancer Society, ScaleHealth, Impact Venture Partners.
Deck Bio is headquartered in Cambridge, United States.
Deck Bio develops multi-target T cell engager immunotherapies for solid tumors.
Deck Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Deck Bio — Funding & Investors." VCBacked, April 9, 2026, https://www.vcbacked.co/company/deck-bio. Accessed September 30, 2026.
VCBacked. (2026). Deck Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/deck-bio
{{cite web |title=Deck Bio — Funding & Investors |url=https://www.vcbacked.co/company/deck-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated